curasan AG, listed in the Prime Standard of the Frankfurt Stock Exchange, has sold its dental products division to Riemser Arzneimittel AG with effect as of July 1, 2008. The deal is worth approximately EUR 15 million.
curasan AG is a leader in the area of bone and tissue regeneration. As part of the sale of the dental division, all related intangible assets, licences and trademarks for Cerasorb® and REVOIS® as well as REVOIS® patents, customer and supplier relationships and distribution licences will be transferred to Riemser Arzneimittel AG. In addition, all shares in curasan Inc., USA, along with the majority of the staff will transfer to the acquirer.
The following Gleiss team advised curasan AG: Dr. Detlef Bauer and Dr. Stephan Aubel (both partners, lead, corporate/M&A, capital markets), Dr. Thomas Richter and Holger Ebersberger (both corporate/M&A) as well as Dr. Bettina Bubach (employment) (all Frankfurt).
Forward
